Evaluation of Hepatic Blood Flow Alteration in Celecoib Combined with TAE Treated Liver Vx2 Tumor Rabbits

王于,连帆,李家平,李鹤平,陈伟,杨建勇
DOI: https://doi.org/10.3969/j.issn.1009-4393.2009.35.031
2009-01-01
Abstract:Objective Evaluation of hepatic blood flow alteration in Celecoib combined with TAE in vx2 tumor rabbits.Material and methods 19 vx2 tumor rabbits randomly grouped as A(n=5) medication group fed with celecoxib,B(n=6) underwent TAE,C(n=8) treated by TAE plus celecoxib.Group A underwent CT scan in day 1 and day 15 after medication.Rabbits were sacrificed after second CT scan.Group B,C undewent angiography and embolism by trans-Gastroduodenal Artery catheterize hepatic artery reversely after laparotomy and CT perfusion scan in day 1 and 15 after TAE.Rabbits were sacrificed in day 15.All followed by HE and IHC staining.Results CT scan revealed that group A had more blood supply in HAP and THBF.No significance showed in day 1 and day 15.HAP and THBF decreased significantly in day 1 after TAE in Group B.PVP was of no significance.HAP and THBF recovered in day 15.HAP and PVP decreased in Group C in day 1,not as severe as Group B.HAP and THBF achieved the same level as before procedure on day 15.Conclusion COX-2 inhibitors alleviated reduction of HAP and THBF after TAE in early stage.However,no benefit was found in late stage,which projected COX-2 inhibitors may be the candidate protective factor in TAE in early stage.
What problem does this paper attempt to address?